Latest news
25.03.2021
DEINOVE presents its financial results and the advancement of its programs for 2020
Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected mid-2021 Signature of an...
10.03.2021
DEINOVE benefits from the support of the French government, within the framework of the “France Relance” plan, to accelerate the development of new antimicrobials
DEINOVE’s Boost-ID project has been selected as part of the “France Relance” plan, a recognition of its strategic positioning. Boost-ID is...
21.01.2021
DEINOVE strenghtens its Business development team to deploy its partnering strategy
Hervé Ansanay, PhD, former Technology transfer and Business Development Director of the SATT AxLR of Montpellier, is appointed Business...
Press Coverage
09.03.2021
La Gazette de Montpellier - Live - Le projet Boost ID de la biotech montpelliéraine DEINOVE
12.05.2020
Cdiff Foundation | A New Parenteral Treatment for a Severe C. difficile Infection
"A New Parenteral Treatment for a Severe C. difficile Infection" hosted by Nancy C. Caralla Join us with our two guests: Dr Yannick Pletan...
08.05.2020
Biotech & Finance | Alexis Rideau, arrive chez Deinove avec son réseau industriel et académique de pointe
C’est une nouvelle aventure pour Alexis Rideau, qui occupe depuis cette semaine la fonction de directeur général délégué de Deinove...